{"id":17386,"date":"2020-06-16T17:44:27","date_gmt":"2020-06-16T15:44:27","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=17386"},"modified":"2020-06-16T17:44:28","modified_gmt":"2020-06-16T15:44:28","slug":"inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\/","title":{"rendered":"Inclusieve Vaccin Alliantie sluit deal met AstraZeneca"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">De Inclusieve Vaccine Alliantie (IVA) heeft\nafspraken gemaakt met AstraZeneca over de levering van in totaal 300 tot 400\nmiljoen doses van het COVID-19-vaccin AZD1222 van de Oxford Universiteit. Als\nalles goed gaat, worden de eerste leveringen voor het einde van dit jaar\nverwacht. Binnen de IVA bundelen Duitsland, Frankrijk, Itali\u00eb en Nederland de\nkrachten in de onderhandeling met ontwikkelaars en producenten van potenti\u00eble\ncoronavaccins. De deal met AstraZeneca zijn de eerste afspraken van de\nalliantie om te zorgen dat een potentieel coronavaccin voor Europa snel beschikbaar\nkan komen.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">De corona-pandemie stelt de wereld voor ongekende uitdagingen. Wereldwijd bundelen partijen de krachten om zo snel mogelijk effectieve vaccins en geneesmiddelen te ontwikkelen. Dat vergt meer dan investeren in onderzoek alleen. In een recente <a href=\"https:\/\/read.oecd-ilibrary.org\/view\/?ref=133_133372-v717pcul4c&amp;title=Treatments-and-a-vaccine-for-COVID-19-the-need-for-coordinating-policies-on-RD-manufacturing-and-access\"><strong>publicatie<\/strong><\/a> gaat de Organisatie voor Economische Samenwerking en Ontwikkeling (OESO) in op de vraag hoe beleid de eerlijke en universele toegang tot behandelingen en vaccins voor het coronavirus kan stimuleren. De OESO adviseert publieke partijen ook later in het proces te investeren, te helpen om het risico te dragen, pull mechanismen uit te werken, om productiecapaciteit uit te breiden parallel aan ontwikkeling en bovenal grootschalige internationale samenwerking. Met haar aanpak lijkt de IVA die aanbevelingen ter harte te nemen. <\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Lees meer<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li><a href=\"https:\/\/www.astrazeneca.nl\/newsroom\/press-releases\/AstraZeneca-levert-vaccin-Oxford-University-aan-Europa.html\">https:\/\/www.astrazeneca.nl\/newsroom\/press-releases\/AstraZeneca-levert-vaccin-Oxford-University-aan-Europa.html<\/a><\/li><li><a href=\"https:\/\/www.rijksoverheid.nl\/actueel\/nieuws\/2020\/06\/13\/mogelijk-coronavaccin-voor-europa-gecontracteerd\">https:\/\/www.rijksoverheid.nl\/actueel\/nieuws\/2020\/06\/13\/mogelijk-coronavaccin-voor-europa-gecontracteerd<\/a><\/li><li><a href=\"https:\/\/read.oecd-ilibrary.org\/view\/?ref=133_133372-v717pcul4c&amp;title=Treatments-and-a-vaccine-for-COVID-19-the-need-for-coordinating-policies-on-RD-manufacturing-and-access\">https:\/\/read.oecd-ilibrary.org\/view\/?ref=133_133372-v717pcul4c&amp;title=Treatments-and-a-vaccine-for-COVID-19-the-need-for-coordinating-policies-on-RD-manufacturing-and-access<\/a><\/li><\/ul>\n","protected":false},"excerpt":{"rendered":"<p>De Inclusieve Vaccine Alliantie (IVA) heeft afspraken gemaakt met AstraZeneca over de levering van in totaal 300 tot 400 miljoen doses van het COVID-19-vaccin AZD1222 van de Oxford Universiteit. Als alles goed gaat, worden de eerste leveringen voor het einde van dit jaar verwacht. Binnen de IVA bundelen Duitsland, Frankrijk, Itali\u00eb en Nederland de krachten [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[39,43],"tags":[],"class_list":["post-17386","post","type-post","status-publish","format-standard","hentry","category-gezondheid","category-innovatieklimaat"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Inclusieve Vaccin Alliantie sluit deal met AstraZeneca - hollandbio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inclusieve Vaccin Alliantie sluit deal met AstraZeneca - hollandbio\" \/>\n<meta property=\"og:description\" content=\"De Inclusieve Vaccine Alliantie (IVA) heeft afspraken gemaakt met AstraZeneca over de levering van in totaal 300 tot 400 miljoen doses van het COVID-19-vaccin AZD1222 van de Oxford Universiteit. Als alles goed gaat, worden de eerste leveringen voor het einde van dit jaar verwacht. Binnen de IVA bundelen Duitsland, Frankrijk, Itali\u00eb en Nederland de krachten [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\/\" \/>\n<meta property=\"og:site_name\" content=\"hollandbio\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-16T15:44:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-06-16T15:44:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"hollandbio\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:site\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hollandbio\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\\\/\"},\"author\":{\"name\":\"hollandbio\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\"},\"headline\":\"Inclusieve Vaccin Alliantie sluit deal met AstraZeneca\",\"datePublished\":\"2020-06-16T15:44:27+00:00\",\"dateModified\":\"2020-06-16T15:44:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\\\/\"},\"wordCount\":240,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"articleSection\":[\"Gezondheid\",\"Innovatieklimaat\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\\\/\",\"name\":\"Inclusieve Vaccin Alliantie sluit deal met AstraZeneca - hollandbio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\"},\"datePublished\":\"2020-06-16T15:44:27+00:00\",\"dateModified\":\"2020-06-16T15:44:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inclusieve Vaccin Alliantie sluit deal met AstraZeneca\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"name\":\"hollandbio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\",\"name\":\"hollandbio\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"width\":218.664,\"height\":29.659,\"caption\":\"hollandbio\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hollandbio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hollandbio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/833d6a25b39946e61c6101af1fa96fbb\",\"name\":\"hollandbio\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inclusieve Vaccin Alliantie sluit deal met AstraZeneca - hollandbio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hollandbio.nl\/en\/nieuws\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\/","og_locale":"en_US","og_type":"article","og_title":"Inclusieve Vaccin Alliantie sluit deal met AstraZeneca - hollandbio","og_description":"De Inclusieve Vaccine Alliantie (IVA) heeft afspraken gemaakt met AstraZeneca over de levering van in totaal 300 tot 400 miljoen doses van het COVID-19-vaccin AZD1222 van de Oxford Universiteit. Als alles goed gaat, worden de eerste leveringen voor het einde van dit jaar verwacht. Binnen de IVA bundelen Duitsland, Frankrijk, Itali\u00eb en Nederland de krachten [&hellip;]","og_url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\/","og_site_name":"hollandbio","article_published_time":"2020-06-16T15:44:27+00:00","article_modified_time":"2020-06-16T15:44:28+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","type":"image\/png"}],"author":"hollandbio","twitter_card":"summary_large_image","twitter_creator":"@hollandbio","twitter_site":"@hollandbio","twitter_misc":{"Written by":"hollandbio","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\/#article","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\/"},"author":{"name":"hollandbio","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb"},"headline":"Inclusieve Vaccin Alliantie sluit deal met AstraZeneca","datePublished":"2020-06-16T15:44:27+00:00","dateModified":"2020-06-16T15:44:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\/"},"wordCount":240,"publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"articleSection":["Gezondheid","Innovatieklimaat"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\/","url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\/","name":"Inclusieve Vaccin Alliantie sluit deal met AstraZeneca - hollandbio","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/#website"},"datePublished":"2020-06-16T15:44:27+00:00","dateModified":"2020-06-16T15:44:28+00:00","breadcrumb":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hollandbio.nl\/en\/nieuws\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/inclusieve-vaccin-alliantie-sluit-deal-met-astrazeneca\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hollandbio.nl\/en\/"},{"@type":"ListItem","position":2,"name":"Inclusieve Vaccin Alliantie sluit deal met AstraZeneca"}]},{"@type":"WebSite","@id":"https:\/\/www.hollandbio.nl\/en\/#website","url":"https:\/\/www.hollandbio.nl\/en\/","name":"hollandbio","description":"","publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hollandbio.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.hollandbio.nl\/en\/#organization","name":"hollandbio","url":"https:\/\/www.hollandbio.nl\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","contentUrl":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","width":218.664,"height":29.659,"caption":"hollandbio"},"image":{"@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hollandbio","https:\/\/www.linkedin.com\/company\/hollandbio\/"]},{"@type":"Person","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/833d6a25b39946e61c6101af1fa96fbb","name":"hollandbio"}]}},"_links":{"self":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/17386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/comments?post=17386"}],"version-history":[{"count":0,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/17386\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/media?parent=17386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/categories?post=17386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/tags?post=17386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}